<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617613</url>
  </required_header>
  <id_info>
    <org_study_id>MKH-01-2016</org_study_id>
    <nct_id>NCT04617613</nct_id>
  </id_info>
  <brief_title>Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait</brief_title>
  <official_title>Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Kuwait</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Azhar University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eradication of H. pylori reduces morbidity in patients with chronic gastritis and can prevent&#xD;
      gastric cancer. We aimed to evaluate the efficacy of clarithromycin-based triple therapy and&#xD;
      non-bismuth based quadruple therapy for eradicating H. pylori in patients with chronic&#xD;
      gastritis in Kuwait.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (H. pylori) induced chronic infection is associated with peptic ulcer,&#xD;
      chronic gastritis, gastric cancer, and increasing antibiotic resistance. Eradication of H.&#xD;
      pylori reduces morbidity in patients with chronic gastritis and can prevent gastric cancer in&#xD;
      the high-risk population. We aimed to evaluate the efficacy of clarithromycin-based triple&#xD;
      therapy and non-bismuth based quadruple therapy for eradicating H. pylori in patients with&#xD;
      chronic gastritis in Kuwait. We enrolled treatment-naive dyspeptic patients with gastric&#xD;
      biopsy-proven chronic gastritis secondary to H. pylori in a prospective, open-label,&#xD;
      randomized study conducted at the gastroenterology outpatient clinics of Haya Habeeb&#xD;
      gastroenterology center in Kuwait. Patients were randomized into two groups: the first group&#xD;
      received the standard triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14&#xD;
      days; and the second group received quadruple therapy (omeprazole, amoxicillin,&#xD;
      clarithromycin, and metronidazole) for 14 days. All patients were tested for the eradication&#xD;
      of H. pylori by carbon-13 urea breath test (13C-UBT) one month after completion of&#xD;
      eradication therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative 13-Carbon urea breath test</measure>
    <time_frame>One month</time_frame>
    <description>H. pylori eradication rate defined as negative 13-Carbon urea breath test (13C-UBT) one month after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>One month</time_frame>
    <description>Any reported adverse events during the study period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Standard triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole, Amoxicillin, Metronidazole and Clarithromycin</intervention_name>
    <description>The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.</description>
    <arm_group_label>Quadruple therapy group</arm_group_label>
    <other_name>Quadruple therapy group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole, Amoxicillin and Clarithromycin</intervention_name>
    <description>The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.</description>
    <arm_group_label>Standard triple therapy</arm_group_label>
    <other_name>Standard triple therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female dyspeptic subjects aged â‰¥18 years with any nationality&#xD;
&#xD;
          -  Patients with gastric biopsy-proven H. pylori related chronic gastritis and no other&#xD;
             abnormalities in the upper gastrointestinal tract upon endoscopy&#xD;
&#xD;
          -  Patients who were naive to treatment for H. pylori infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding females&#xD;
&#xD;
          -  Patients who were previously treated for H. pylori infection&#xD;
&#xD;
          -  Patients who received any antibiotics, bismuth or acid-suppressant drugs within the&#xD;
             last month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Azhar University</investigator_affiliation>
    <investigator_full_name>Mohamed Alboraie</investigator_full_name>
    <investigator_title>Postgraduate clinical researcher</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

